retatrutide triple agonist gip glp-1 glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept Targeting GLP-1, GIP & GCG
Description
Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes
Omarigliptin: First global approval
It's unflavored and is made of a grit-free powder that dissolves completely in hot or cold liquid
This comparison matters because many people consider Pendulum specifically as an alternative to medications like semaglutide and tirzepatide
Conclusion Both GLP-1 agonists and SGLT2 inhibitors represent significant advances in Type 2 diabetes care
